Qure (NasdaqGS:QURE) is back in focus after the FDA said three year Phase I/II data for its Huntington’s disease gene therapy, AMT-130, can form the basis of a Biologics License Application, prompting ...
Below is Validea's guru fundamental report for UNIQURE NV (QURE). Of the 22 guru strategies we follow, QURE rates highest using our Value Investor model based on the published strategy of Benjamin ...
Shares of uniQure N.V. QURE plunged 31.8% in a week, primarily after the company announced a disappointing regulatory update for its investigational gene therapy, AMT-130, for the treatment of ...
uniQure's lead candidate AMT-130 targets Huntington's disease with promising clinical data and potential for accelerated FDA approval, driving my continued Buy rating. The company has strong cash ...
uniQure N.V. QURE stock is up during Wednesday’s premarket session as the company announced plans for a Biologics License ...
Shares of uniQure N.V.QURE skyrocketed 247.7% on Wednesday after the company reported meeting key goals in the pivotal early to mid-stage study of its investigational gene therapy, AMT-130, for the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
uniQure NV (NASDAQ: QURE) stock has plunged around 31% over the last month, as per data from Benzinga Pro. • uniQure stock is trading at depressed levels. Where are QURE shares going? UniQure stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results